Abstract
Chemotherapy is one of the important treatment modules in early as well as advanced stages of cancer. However, the major limitation of chemotherapy is the development of chemoresistance in the transformed cells of cancer patients, which leads to cancer recurrence. Long non-coding RNAs (lncRNA) are the transcripts longer than 200 nucleotides in length, which are reported to associate with the initiation, progression, recurrence, and metastasis of different cancers. Several lncRNAs have been implicated in the prevalence of chemoresistant phenotypes and also in the restoration of drug sensitivity in chemoresistant cells. LncRNAs such as HOTAIR, H19, and a lot more are involved in the chemoresistance of cancer cells. Therefore, targeting the lncRNAs may serve as a novel strategy for treating chemoresistant cancer. This review throws light on the role of lncRNA in chemoresistance along with the perspective of the therapeutic targets for the treatment of multiple cancers.
Similar content being viewed by others
References
Panoutsopoulou K, Avgeris M, Scorilas A (2018) miRNA and long non-coding RNA: molecular function and clinical value in breast and ovarian cancers. Expert. Rev. Mol Diagn 18:963–979
Uchida S, Adams JC (2019) Physiological roles of non-coding RNAs. Am J Physiol Cell Physiol 317:C1–C2
Agostini M, Ganini C, Candi E, Melino G (2020) The role of noncoding RNAs in epithelial cancer. Cell Death Discov 6:13
Huang T, Alvarez A, Hu B, Cheng SY (2013) Noncoding RNAs in cancer and cancer stem cells. Chin J Cancer 11:582–593
Fang Y, Fullwood MJ (2016) Roles, functons, and mechanism of Long non-coding RNAs in Cancer. Genomics Proteomics Bioinform 14:42–54
Singh D, Khan MA, Siddique HR (2019) Apigenin, a plant flavone playing Noble roles in Cancer prevention via modulation of key cell signaling networks. Recent Pat Anticancer Drug Discov 14:298–311
Brasseur K, Gévry N, Asselin E (2017) Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget. 8:4008–4042
Bermúdez M, Aguilar-Medina M, Lizárraga-Verdugo E, Avendaño-Félix M, Silva-Benítez E, López-Camarillo C, Ramos-Payan R (2019) LncRNAs as regulators of autophagy and drug resistance in colorectal Cancer. Front Oncol 9:1008
Liu Z, Sun M, Lu K, Liu J, Zhang M, Wu W, De W, Wang Z, Wang R (2013) The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression. PLoS ONE 8:e77293
Liu J, Wan L, Lu K, Sun M, Pan X, Zhang P, Lu B, Liu G, Wang Z (2015) The long noncoding RNA MEG3 contributes to cisplatin resistance of human lung adenocarcinoma. PLoS ONE 10:e0114586
Li Z, Zhao X, Zhou Y, Liu Y, Zhou Q, Ye H, Wang Y, Zeng J, Song Y, Gao W, Zheng S, Zhuang B, Chen H, Li W, Li H, Li H, Fu Z, Chen R (2015) The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer. J Transl Med 13(84)
Takahashi K, Yan IK, Kogure T, Haga H, Patel T (2014) Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer. FEBS Open Bio 4:458–467
Niazi F, Valadkhan S (2012) Computational analysis of functional long noncoding RNAs reveals lack of peptide coding capacity and parallels with 3′ UTRs. RNA. 18:825–843
Novikova IV, Hennelly SP, Sanbonmatsu KY (2012) Sizing up long non-coding RNAs: do lncRNAs have secondary and tertiary structure. Bioarchitecture. 2:189–199
Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, Li R, West RB, van de Vijver MJ, Sukumar S, Chang HY (2010) Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 464:1071–1076
Laurent GS, Wahlestedt C, Kapranov P (2015) The landscape of long noncoding RNA classification. Trends Genet 31:239–251
Zheng HC (2017) The molecular mechanisms of chemoresistance in cancers. Oncotarget. 8:59950–59964
Liu K, Gao L, Ma X, Huang JJ, Chen J, Zeng L, Ashby CR, Zou C, Chen ZS (2020) Long non-coding RNAs regulate drug resistance in cancer. Mol Cancer 19:54
Ozes AR, Miller DF, Ozes ON, Fang F, Liu Y, Matei D, Huang T, Nephew KP (2016) NF-kappa-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer. Oncogene. 35:5350–5361
Fang S, Gao H, Tong Y, Yang J, Tang R, Niu Y, Li M, Guo L (2016) Long noncoding RNA-HOTAIR affects chemoresistance by regulating HOXA1 methylation in small cell lung cancer cells. Lab Investig 96:60–68
Xue X, Yang YA, Zhang A, Fong KW, Kim J, Song B, Li S, Zhao JC, Yu J (2016) LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene. 35:2746–2755
Wang Y, Zhang D, Wu K, Zhao Q, Nie Y, Fan D (2014) Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. Mol Cell Biol 34:3182–3193
Dong S, Qu X, Li W, Zhong X, Li P, Yang S, Chen X, Shao M, Zhang L (2015) The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression. J Hematol Oncol 8:43
Gao ZQ, Wang JF, Chen DH, Ma XS, Yang W, Zhe T, Dang XW (2018) Long non-coding RNA GAS5 antagonizes the chemoresistance of pancreatic cancer cells through down-regulation of miR-181c-5p. Biomed Pharmacother 97:809–817
Cheng N, Cai W, Ren S, Li X, Wang Q, Pan H, Zhao M, Li J, Zhang Y, Zhao C, Chen X, Fei K, Zhou C, Hirsch FR (2015) Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer. Oncotarget. 6:23582–23593
Wang H, Guan Z, He K, Qian J, Cao J, Teng L (2017) LncRNA UCA1 in anti-cancer drug resistance. Oncotarget. 8:64638–64650
Bian Z, ** L, Zhang J, Yin Y, Quan C, Hu Y, Feng Y, Liu H, Fei B, Mao Y, Zhou L, Qi X, Huang S, Hua D, **ng C, Huang Z (2016) LncRNA—UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p. Sci Rep UK 6:23892
Shi SJ, Wang LJ, Yu B, Li YH, ** Y, Bai XZ (2015) LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget. 6:11652–11663
Han P, Li JW, Zhang BM, Lv JC, Li YM, Gu XY, Yu ZW, Jia YH, Bai XF, Li L, Liu YL, Cui BB (2017) The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signalling. Mol Cancer 16:9
Niu Y, Ma F, Huang W, Fang S, Li M, Wei T, Guo L (2017) Long non-coding RNA TUG1 is involved in cell growth and chemoresistance of small cell lung cancer by regulating LIMK2b via EZH2. Mol Cancer 16:5
Ren K, Xu R, Huang J, Zhao J, Shi W (2017) Knockdown of long non-coding RNA KCNQ1OT1 depressed chemoresistance to paclitaxel in lung adenocarcinoma. Cancer Chemother Pharmacol 80:243–250
Jiang YZ, Liu YR, Xu XE, ** X, Hu X, Yu KD, Shao ZM (2016) Transcriptome analysis of triple-negative breast Cancer reveals an integrated mRNA-lncRNA signature with predictive and prognostic value. Cancer Res 76:2105–2114
Zhang C, Zhu K, Shen G, Zhu Z (2016) A long non-coding RNA contributes to doxorubicin resistance of osteosarcoma. Tumor Biol 37:2737–2748
Lee H, Kim C, Ku J, Kim W, Yoon SK, Kuh HJ, Lee JH, Nam SW, Lee EK (2014) A Long non-coding RNA snaR contributes to 5-fluorouracil resistance in human Colon Cancer cells. Mol Cells 37:540–546
Ma Y, Yang Y, Wang F, Moyer MP, Wei Q, Zhang P, Yang Z, Liu W, Zhang H, Chen N, Wang H, Wang H, Qin H (2015) Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/ -catenin signalling pathway via suppression of activator protein 2. Gut. 65:1494–1504
Qu L, Ding J, Chen C, Wu Z, Liu B, Gao Y, Chen W, Liu F, Sun W, Li XF, Wang X, Wang Y, Xu ZY, Gao L, Yang Q, Xu B, Li YM, Fang ZY, Xu ZP, Bao Y, Wu DS, Miao X, Sun HY, Sun YH, Wang HY, Wang LH (2016) Exosome-transmitted lncARSR promotes Sunitinib resistance in renal Cancer by acting as a competing endogenous RNA. Cancer Cell 29:653–668
Pan Y, Li C, Chen J, Zhang K, Chur X, Wang R, Chen L (2016) The emerging roles of Long noncoding RNA ROR (lincRNA-ROR) and its possible mechanisms in human cancers. Cell Physiol Biochem 40:219–229
Liu E, Liu Z, Zhou Y, Mi R, Wang D (2015) Overexpression of long non-coding RNA PVT1 in ovarian cancer cells promotes cisplatin resistance by regulating apoptotic pathways. Int J Clin Exp Med 8:20565–20572
Sun ZY, Jian YK, Zhu HY, Li B (2019) lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway. Pathol Res Pract 215:555–563
Kun-Peng Z, **ao-Long M, Chun-Lin Z (2018) Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1. Int J Biol Sci 14:321–330
Wang KC, Yang YW, Liu B, Sanyal A, Corces-Zimmerman R, Chen Y, Lajoie BR, Protacio A, Flynn RA, Gupta RA, Wysocka J, Lei M, Dekker J, Helms JA, Chang HY (2011) A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature. 472:120–124
Yang F, Deng X, Ma W, Berletch JB, Rabaia N, Wei G, Moore JM, Filippova GN, Xu J, Liu Y, Noble WS, Shendure J, Disteche CM (2015) The lncRNA Firre anchors the inactive X chromosome to the nucleolus by binding CTCF and maintains H3K27me3 methylation. Genome Biol 16:52
Do H, Kim W (2018) Roles of oncogenic Long non-coding RNAs in Cancer development. Genomics Inform 4:e18
Li Y, Wang Z, Shi H, Li H, Li L, Fang R, Cai X, Liu B, Zhang X, Ye L (2015) HBXIP and LSD1 Scaffolded by lncRNA hotair mediate transcriptional activation by c-Myc. Cancer Res 76:293
Nie W, Ge HJ, Yang XQ, Sun X, Huang H, Tao X, Chen WS, Li B (2016) LncRNA-UCA1 exerts oncogenic functions in non-small cell lung cancer by targeting miR-193a-3p. Cancer Lett 371:99–106
Peng W, Si S, Zhang Q, Li C, Zhao F, Wang F, Yu J, Ma R (2015) Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate gastric cancer progression. J Exp Clin Cancer Res 34:79
Deng L, Yang SB, Xu FF, Zhang JH (2015) Long noncoding RNA CCAT1 promotes hepatocellular carcinoma progression by functioning as let-7 sponge. J Exp Clin Cancer Res 34:18
Lee S, Kopp F, Chang TC, Sataluri A, Chen B, Sivakumar S, Yu H, **e Y, Mendell JT (2015) Noncoding RNA NORAD regulates genomic stability by sequestering PUMILIO proteins. Cell. 164:69
Inamura K (2017) Major tumor suppressor and oncogenic non-coding RNAs: clinical relevance in lung Cancer. Cells. 6:12
Fatma H, Siddique HR (2020) Role of long non-coding RNAs and MYC interaction in cancer metastasis: a possible target for therapeutic intervention. Tox App Pharmacol 399
Guo F, Guo L, Li Y, Zhou Q, Li Z (2015) MALAT1 is an oncogenic long non-coding RNA associated with tumor invasion in non-small cell lung cancer regulated by DNA methylation. Int J Clin Exp Pathol 8:15903–15910
Liu XH, Sun M, Nie FQ, Ge YB, Zhang EB, Yin DD, Kong R, **a R, Lu KH, Li JH, De W, Wang KM, Wang ZX (2014) LncRNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol Cancer 13:92
Liu Y, Sun M, **a R, Zhang EB, Liu XH, Zhang ZH, Xu TP, De W, Liu BR, Wang ZX (2015) LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer. Cell Death Disease 6:e1802
Hajjari M, Salavaty A (2015) HOTAIR: an oncogenic long non-coding RNA in different cancers. Cancer Biol Med 12:1–9
Zhang A, Zhao JC, Kim J, Fong K, Yang YA, Chakravarti D, Mo YY, Yu JI (2015) HOTAIR enhances the androgen-receptor-mediated transcriptional program and drives castration-resistant prostate cancer. Cell Rep 13:209–221
Godinho M, Meijer D, Setyono-Han B, Dorssers LCJ, Van Agthoven T (2011) Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells. J Cell Physiol 226:1741–1749
Van Agthoven T, Dorssers LC, Lehmann U, Kreipe H, Looijenga LH, Christgen M (2015) Breast Cancer anti-Estrogen resistance 4 (BCAR4) drives proliferation of IPH-926 lobular carcinoma cells. PLoS ONE 10:e136845
Han Y, Ye J, Wu D, Wu P, Chen Z, Chen J, Gao S, Huang J (2014) LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition. BMC Cancer 14:932
Fang X, Pan H, Leng R, Ye D (2015) Long noncoding RNAs: novel insights into gastric cancer. Can Lett 356:357–366
Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, Yang H, Samadi AK, Russo GL, Spagnuolo C, Ray SK, Chakrabarti M, Morre JD, Coley HM, Honoki K, Fujii H et al (2015) Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol 35:S78–S103
Zhang X, Bu P, Liu L, Zhang X, Li J (2015) Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem Biophys Res Commun 462:227–232
Shang C, Guo Y, Zhang J, Huang B (2016) Silence of long noncoding RNA UCA1 inhibits malignant proliferation and chemotherapy resistance to adriamycin in gastric cancer. Cancer Chemoth Pharm 77:1061–1067
Wang F, Li X, **e X, Zhao L, Chen W (2008) UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. FEBS Lett 582:1919–1927
Wang Y, Chen W, Yang C, Wu W, Wu S, Qin X, Li X (2012) Long non-coding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of bladder cancer. Int J Oncol 41:276–284
Lan WG, Xu DH, Xu C, Ding CL, Ning FL, Zhou YL, Ma LB, Liu CM, Han X (2016) Silencing of long non-coding RNA ANRIL inhibits the development of multidrug resistance in gastric cancer cells. Oncol Rep 36:263–270
Wan L, Sun M, Liu GJ, Wei CC, Zhang EB, Kong R, Xu TP, Huang MD, Wang ZX (2016) Long non-coding RNA PVT1 promotes non-small cell lung cancer cell proliferation through epigenetically regulating LATS2 expression. Mol Cancer Ther 15:1082–1094
Cheng N, Li X, Zhao C, Ren S, Chen X, Cai W, Zhao M, Zhang Y, Li J, Wang Q, Zhou C (2015) Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer. Oncol Rep 33:833–839
Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM (2013) Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 144:512–527
Jiang M, Huang O, **e Z, Wu S, Zhang X, Shen A, Liu H, Chen X, Wu J, Lou Y, Mao Y, Sun K, Hu S, Geng M, Shen K (2014) A novel long non-coding RNA-ARA: Adriamycin resistance-associated. Biochem Pharmacol 87:254–283
Souza PS, Madigan JP, Gillet JP, Kapoor K, Ambudkar SV, Maia RC, Gottesman MM, Fung KL (2015) Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL. Exp Cell Res 336:318–328
Tsang WP, Kwok TT (2007) Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene. 26:4877–4881
Huang L, Zeng L, Chu J, Xu P, Lv M, Xu J, Wen J, Li W, Wang L, Wu X, Fu Z, **e H, Wang S (2018) Chemoresistance-related long non-coding RNA expression profiles in human breast cancer cells. Mol Med Rep 18:243–253
Vendrell JA, Thollet A, Nguyen NT, Ghayad SE, Vinot S, Ivan B, Evelyne G, Veronique J, Jean-Luc C, Pierre R, Laura C, Isabelle T, Ruth R, Pascale C (2012) ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion. Cancer Res 72:3593–3606
Yang Y, Li H, Hou S, Hu B, Liu J, Wang J (2013) The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small- cell lung Cancer cell. PLoS ONE 8:e65309
Cai Y, He J, Zhang D (2016) Suppression of long non-coding RNA CCAT2 improves tamoxifen-resistant breast cancer cells’ response to tamoxifen. Mol Biol (Mosk) 50(821–7)
Li Z, Qian J, Li J, Zhu C (2019) Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway. Exp Ther Med 18:435–442
Li W, Zhai L, Wang H, Liu C, Zhang J, Chen W, Wei Q (2016) Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer. Oncotarget. 7:27778–27786
Kimura T, Aikata H, Takahashi S, Takahashi I, Nishibuchi I, Doi Y, Kenjo M, Murakami Y, Honda Y, Kakizawa H, Awai K, Chayama K, Nagata Y (2015) Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies. Hepatol Res 45:378–386
Arjmand F, Afsan Z, Sharma S, Parveen S, Yousuf I, Sartaj S, Siddique HR, Tabassum S (2019) Recent advances in Metallodrug-like molecules targeting non-coding RNAs (ncRNAs) in cancer chemotherapy. Coord Chem Rev 387:47–59
Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, Zand B, Matsuo K, Shahzad MM, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Calin GA (2013) Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov 3:1302–1315
Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C (2015) The ZNF304-integrin axis protects against anoikis in cancer. Nat Commun 6:7351
Ozpolat B, Sood AK, Lopez-Berestein G (2014) Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev 66:110–116
Gutschner T, Hämmerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, Zörnig M, MacLeod AR, Spector DL, Diederichs S (2013) The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res 73:1180–1189
Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, **ong Y (2011) Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene. 30:1956–1962
Geary RS, Norris D, Yu R, Bennett CF (2015) Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 87:46–51
Shen X, Corey DR (2018) Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res 46:1584–1600
Yang G, Lu X, Yuan L (2014) LncRNA: a link between RNA and cancer. Biochim Biophys Acta 1839:1097–1109
Iden M, Fye S, Li K, Chowdhury T, Ramchandran R, Rader JS (2016) The lncRNA PVT1 contributes to the cervical cancer phenotype and associates with poor patient prognosis. PLoS ONE 11:e0156274
Durig J, Duhrsen U, Klein-Hitpass L, Worm J, Hansen JB, Orum H, Wissenbach M (2011) The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia. Leukemia. 25:638–647
Carlevaro-Fita J, Rahim A, Guigó R, Vardy LA, Johnson R (2016) Cytoplasmic long noncoding RNAs are frequently bound to and degraded at ribosomes in human cells. RNA. 22:867–882
Pavco PA, Bouhana KS, Gallegos AM, Agrawal A, Blanchard KS, Grimm SL, Jensen KL, Andrews LE, Wincott FE, Pitot PA, Tressler RJ, Cushman C, Reynolds MA, Parry TJ (2000) Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 6:2094–2130
Charles Richard JL, Eichhorn PJA (2018) Platforms for investigating LncRNA functions. SLAS Technol 23:493–506
Vitiello M, Tuccoli A, Poliseno L (2015) Long non-coding RNAs in cancer: implications for personalized therapy. Cell Oncol (Dordr) 38(17–28)
Rivas E, Clements J, Eddy SR (2017) A statistical test for conserved RNA structure shows lack of evidence for structure in lncRNAs. Nat Methods 14:45–48
Brown JA, Kinzig CG, DeGregorio SJ, Steitz JA (2014) Methyltransferase-like protein 16 binds the 3′-terminal triple helix of MALAT1 long noncoding RNA. Proc Natl Acad Sci U S A 113:14013–14018
Desoize B (2004) Metals and metal compounds in cancer treatment. Anticancer Res 24:1529–1544
Celander DW, Nussbaum JM (1996) The porphyrin handbook. Biochemistry. 35:12061–12069
Moulton JD (2017) Using morpholinos to control gene expression. Curr Protoc Nucleic Acid Chem 68:1–4
Blum M, De Robertis EM, Wallingford JB, Niehrs C (2015) Morpholinos: antisense and sensibility. Dev Cell 35:145–149
Goemans NM, Tulinius M, Van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, Holling T, Janson AA, Platenburg GJ, Sipkens JA, Sitsen JM, Aartsma-Rus A, van Ommen GJ, Buyse G, Darin N, Verschuuren JJ, Campion GV, de Kimpe SJ, van Deutekom JC (2011) Systemic administration of PRO051 in Duchenne’s muscular dystrophy. N Engl J Med 364:1513–1522
Siddique HR (2016) CRISPR/Cas9 technology: a revolutionary molecular scissors for genome editing and genetic research. MOJ Cell Sci Rep 3:21–24
Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H, Ronning P, Reuland B, Guenther K, Beadnell TC, Essig J, Otto GM, O'Sullivan MG, Largaespada DA, Schwertfeger KL, Marahrens Y, Kawakami Y, Bagchi A (2014) PVT1 dependence in cancer with MYC copy-number increase. Nature. 512:82–86
Zhen S, Hua L, Liu YH, Sun XM, Jiang MM, Chen W, Zhao L, Li X (2017) Inhibition of long non-coding RNA UCA1 by CRISPR/Cas9 attenuated malignant phenotypes of bladder cancer. Oncotarget. 8:9634–9646
Goyal A, Myacheva K, Gross M, Klingenberg M, Duran Arque B, Diederichs S (2017) Challenges of CRISPR/Cas9 applications for long non-coding RNA genes. Nucleic Acids Res 45:e12
Jiang W, **a J, **e S, Zou R, Pan S, Wang ZW, Assaraf YG, Zhu X (2020) Long non-coding RNAs as a determinant of cancer drug resistance: towards the overcoming of chemoresistance via modulation of lncRNAs. Drug Res Updates 50:100683
Huarte M (2015) The emerging role of lncRNAs in cancer. Nat Med 21:1253–1261
Rocha CR, Silva MM, Quinet A, Cabral-Neto JB, Menck CF (2018) DNA repair pathways and cisplation resistance: an intimate relationship. Clinics 73(e478s)
Acknowledgements
We apologize to the eminent researches working in this field whose work has not been cited due to space limitations. The authors are thankful to the Chairman, Department of Zoology, Aligarh Muslim University for his necessary help. DS and MAK express their gratitude to the Council of Scientific and Industrial Research, New Delhi for fellowship.
Funding
This study was funded by the University Grants Commission [F.30-377/2017(BSR)], Department of Science and Technology, Government of India) [EMR/2017/001758] and Council of Scientific and Industrial Research, India [524/(CSIR-UGC-NET) June 2019].
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Singh, D., Khan, M.A. & Siddique, H.R. Emerging role of long non-coding RNAs in cancer chemoresistance: unravelling the multifaceted role and prospective therapeutic targeting. Mol Biol Rep 47, 5569–5585 (2020). https://doi.org/10.1007/s11033-020-05609-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-020-05609-x